Pacira BioSciences Grants Inducement Awards to 14 Employees
Pacira BioSciences announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira's Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors without stockholder approval. Four employees received stock options to purchase an aggregate of 58,000 shares of Pacira common stock and 14 employees received restricted stock units for an aggregate of 41,300 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient's first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $21.02 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on February 1, 2027. Vesting of the equity awards is subject to the employee's continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.
Trade with 70% Backtested Accuracy
Analyst Views on PCRX
About PCRX
About the author

- Insider Stock Transaction: On April 23, Pacira BioSciences CFO Shawn Cross exercised 12,941 stock options and immediately sold them for approximately $326,000, indicating a pre-planned liquidity strategy.
- Ownership Change: Following the sale, Cross's direct stock holdings decreased by 10.94%, leaving him with 105,341 shares valued at around $2.67 million, suggesting he maintains a significant ownership stake.
- Market Performance: Despite a modest 0.63% increase in Pacira's stock price over the past year, the stock experienced over a 20% decline at one point in 2026, highlighting its volatility and the need for investors to monitor future financial results closely.
- Product Line Expansion: Pacira generates revenue primarily from non-opioid pain management products, and management emphasized that the upcoming completion of the phase 3 registrational study for Zilretta could present a significant new market opportunity, further driving revenue growth.
- Executive Stock Transaction: On April 23, 2026, Pacira BioSciences CFO Shawn Cross exercised and sold 12,941 shares of common stock for approximately $326,000 at $25.16 per share, indicating a focus on enhancing liquidity.
- Change in Holdings: This transaction represented 10.94% of Shawn Cross's direct common stock holdings, while he retains 150,000 stock options, supporting future liquidity capacity despite the sale.
- Financial Performance Highlights: Pacira reported total revenue of $177 million for Q1 2026, a 5% year-over-year increase that exceeded analyst expectations, reflecting sustained demand in the non-opioid pain management market.
- Market Volatility: Despite a modest 0.63% price change over the past year, Pacira's stock experienced a decline of over 20% at one point in 2026, highlighting the market's keen interest in the company's future developments and clinical trial outcomes.
- Sales Momentum: Pacira BioSciences reported Q1 EXPAREL net sales of $143.3 million, up from $136.5 million in 2025, despite winter storm disruptions, indicating strong market performance with approximately 7% volume growth.
- R&D Progress: Enrollment for a Phase III registrational study in shoulder osteoarthritis has concluded, with top-line results expected later this year, further enhancing the company's innovation and competitive edge in pain management.
- Financial Outlook: The company reiterated its 2026 total revenue guidance of $745 million to $770 million, with EXPAREL net product sales projected between $600 million and $620 million, reflecting confidence in future growth and clarity in strategic planning.
- Share Repurchase Program: In Q1, the company executed $50 million in share repurchases, retiring approximately 2.2 million shares of common stock, which enhances shareholder value and demonstrates confidence in its financial health.
- Earnings Beat: Pacira BioSciences reported a Q1 non-GAAP EPS of $0.60, exceeding expectations by $0.04, indicating a robust profitability trend that may attract further investor interest.
- Revenue Growth: The company achieved $177 million in revenue for Q1, reflecting a 4.8% year-over-year increase and surpassing expectations by $3.66 million, demonstrating stable product demand and promising future growth potential.
- Share Repurchase Program: Pacira repurchased 2.2 million shares of common stock at an average price of $22.28 per share, costing $50 million, which not only enhances EPS but also reflects the company's confidence in its intrinsic value.
- 2026 Revenue Target: The company outlined a revenue target of $745 million to $770 million for 2026, leveraging its 5x30 strategy to drive margin improvements and pipeline progress, indicating a positive outlook for future growth.
- Conference Participation: PharmaCorp Rx Inc. will deliver a corporate presentation at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026, at 9:30 AM ET in Toronto, showcasing its latest developments in Canadian pharmacy services to attract investor interest in its business model and market potential.
- One-on-One Meeting Opportunities: Senior management will engage in one-on-one meetings during the conference, providing direct interaction opportunities with potential investors, thereby enhancing trust and interest in PharmaCorp and facilitating future capital collaborations.
- Industry Context: The Bloom Burton & Co. Healthcare Investor Conference gathers American, Canadian, and international investors focused on the latest developments in the Canadian healthcare sector, and PharmaCorp's participation will help elevate its visibility and influence within the industry.
- Strategic Goals: PharmaCorp aims to build a national network of community pharmacies by acquiring and supporting succession plans for pharmacy owners, currently operating seven PharmaChoice Canada bannered pharmacies, with plans to continue expanding its market share and enhancing competitiveness.
- Barclays Adjusts Price Target: Barclays has reduced its price target for a specific stock from $27 to $25.
- Market Implications: This adjustment may reflect changing market conditions or company performance expectations.










